| Nov 1 |
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
|
| Oct 31 |
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
|
| Oct 31 |
A promising schizophrenia drug showed mixed results. What does that mean for patients?
|
| Oct 31 |
Bristol-Myers Squibb Company (BMY) Q3 2024 Earnings Call Transcript
|
| Oct 31 |
Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript
|
| Oct 31 |
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
|
| Oct 31 |
Bristol Myers Stock Rises. The Drugmaker Hiked Guidance After Sales Beat.
|
| Oct 31 |
Bristol Myers Screams To A Year-High After Walloping Profit Expectations
|
| Oct 31 |
Bristol Myers Squibb stock rises, Merck moves lower. Here's why.
|
| Oct 31 |
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
|
